Novartis AG and Shire Plc are among drugmakers weighing offers for Belgian eye-medicine company ThromboGenics NV, people familiar with the matter said. Novartis is considered the most likely buyer because it already has a partnership to market ThromboGenics’s Jetrea eye medicine outside of the U.S. The sale may value the company at as much as $1.3 billion, according to sources. Read the full story